Cheong-Weon Cho

Dr. Cheong-Weon Cho

Chungnam National University
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2017 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
GSGi-Ho Son
Gi-Ho Son
BLBeom-Jin Lee
Beom-Jin Lee
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

1 August 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

1 August 2008 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JOJae-Ho Oh
Jae-Ho Oh
HPHyoun-Hyang Park
Hyoun-Hyang Park
KDKi-Young Do
Ki-Young Do
MHManhee Han
Manhee Han
DHDong-Hun Hyun
Dong-Hun Hyun
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

13 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho
A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells

1 January 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JBJong-Suep Baek
Jong-Suep Baek
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho

10 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
HLHye-Jin Lee
Hye-Jin Lee
MJMoses Jeong
Moses Jeong
YNYoung-Guk Na
Young-Guk Na
SKsung-jin kim
sung-jin kim
HLHong-Ki Lee
Hong-Ki Lee
Cheong-Weon ChoCheong-Weon Cho
Cheong-Weon Cho
Nanostructured lipid carriers (NLC) are capable of encapsulating hydrophilic and lipophilic drugs. The present study developed an NLC containing epidermal growth factor (EGF) and curcumin (EGF–Cur-NLC). EGF–Cur-NLC was prepared by a modified water-in-oil-in-water (w/o/w) double-emulsion method. The EGF–Cur-NLC particles showed an average diameter of 331.8 nm and a high encapsulation efficiency (81.1% and 99.4% for EGF and curcumin, respectively). In vitro cell studies were performed using two cell types, NIH 3T3 fibroblasts and HaCaT keratinocytes. The results showed no loss of bioactivity of EGF in the NLC formulation. In addition, EGF–Cur-NLC improved in vitro cell migration, which mimics the wound healing process. Finally, EGF–Cur-NLC was evaluated in a chronic wound model in diabetic rats. We found that EGF–Cur-NLC accelerated wound closure and increased the activity of antioxidant enzymes. Overall, these results reveal the potential of the NLC formulation containing EGF and curcumin to promote healing of chronic wounds.